9 completed, 1 terminated. 6 Phase 1, 5 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 6 | Completed 5, Terminated 1 |
| Phase 2 | 5 | Completed 5 |
Follow fresolimumab: new trials by email Literature Review of fresolimumab trials Research Report on fresolimumab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety of Fresolimumab in the Treatment of Osteogenesis Imperfecta Fresolimumab - Osteogenesis Imperfecta | Phase 1 | Completed | Baylor College of Medicine | 11 | 2017-11-15 | 2024-12-04 |
| SABR-ATAC: A Trial of TGF-beta Inhibition and Stereotactic Ablative Radiotherapy for Early Stage Non-small Cell Lung Cancer Fresolimumab, Stereotactic Body Radiation Therapy - Stage IA Non-Small Cell Lung Carcinoma, Stage IB Non-Small Cell Lung Carcinoma | Phase 1 / Phase 2 | Completed | Maximilian Diehn | 28 | 2016-08-01 | 2024-03-27 |
| A Study of Fresolimumab in Patients With Steroid-Resistant Primary Focal Segmental Glomerulosclerosis (FSGS) fresolimumab, Placebo - Primary Focal Segmental Glomerulosclerosis | Phase 2 | Completed | Genzyme, a Sanofi Company | 36 | 2012-08-01 | 2015-08-26 |
| Safety and Imaging Study of GC1008 in Glioma 89Zr-GC1008, GC1008 - Primary Brain Tumors | Phase 2 | Completed | University Medical Center Groningen | 12 | 2011-12-01 | 2024-05-06 |
| Fresolimumab and Radiotherapy in Metastatic Breast Cancer Fresolimumab, Radiation Therapy - Metastatic Breast Cancer | Phase 2 | Completed | Weill Medical College of Cornell University | 23 | 2011-07-01 | 2019-03-05 |
| Anti-TGF-beta Therapy in Patients With Myelofibrosis monoclonal antibody to TGF-beta - Myelofibrosis, Primary Myelofibrosis | Phase 1 | Terminated | John Mascarenhas | 3 | 2011-02-01 | 2014-12-08 |
| Fresolimumab In Systemic Sclerosis Fresolimumab - Diffuse Systemic Sclerosis | Phase 1 | Completed | Boston University | 18 | 2011-01-01 | 2014-07-16 |
| Anti-TGF Monoclonal Antibody (GC1008) in Relapsed Malignant Pleural Mesothelioma GC1008 - Pleural Malignant Mesothelioma | Phase 2 | Completed | Abramson Cancer Center at Penn Medicine | 14 | 2010-04-01 | 2020-04-10 |
| Safety Study of GC1008 in Patients With Focal Segmental Glomerulosclerosis (FSGS) of Single Doses of GC1008 in Patients With Treatment Resistant Idiopathic FSGS GC1008 - Focal Segmental Glomerulosclerosis | Phase 1 | Completed | Genzyme, a Sanofi Company | 16 | 2007-05-01 | 2014-03-19 |
| Study of GC1008 in Patients With Idiopathic Pulmonary Fibrosis (IPF) GC1008 - Idiopathic Pulmonary Fibrosis | Phase 1 | Completed | Genzyme, a Sanofi Company | 25 | 2005-07-01 | 2015-04-13 |
Brain Neoplasms (1) · Breast Neoplasms (1) · Camurati-Engelmann Syndrome (1) · Carcinoma, Non-Small-Cell Lung (1) · Fibrosis (1) · Glomerulosclerosis, Focal Segmental (1) · Idiopathic Pulmonary Fibrosis (1) · Mesothelioma, Malignant (1) · Osteogenesis Imperfecta (1) · Polycythemia Vera (1) · Primary Myelofibrosis (1) · Scleroderma, Diffuse (1)
Genzyme, a Sanofi Company (3) · Abramson Cancer Center at Penn Medicine (1) · Baylor College of Medicine (1) · Boston University (1) · John Mascarenhas (1) · Maximilian Diehn (1) · University Medical Center Groningen (1) · Weill Medical College of Cornell University (1)
United States (9) · Germany (2) · Italy (2) · Belgium (1) · Brazil (1) · Netherlands (1) · Spain (1) · United Kingdom (1)
Annemiek ME Walenkamp, MD, PhD (1) · Brendan Lee, M.D., Ph.D. (1) · James Stevenson, MD (1) · John Mascarenhas, MD (1) · Maximilian Diehn (1) · Robert Lafyatis, MD (1) · Ronald Hoffman, MD (1) · Sandesh Nagamani, M.D. (1) · Silvia Formenti, M.D. (1) · VReid Sutton, M.D. (1)
PMID 23682558, PMID 24890385, PMID 26098215, PMID 31296256, PMID 33463535, PMID 35113812, PMID 35224732, PMID 39990662